Residual Risk Reduction Method for Wearable Assisting Device

Author(s):  
Hiroyasu IKEDA
Cor et Vasa ◽  
2010 ◽  
Vol 52 (4) ◽  
pp. 212-228
Author(s):  
Jean-Charles Fruchart ◽  
Frank M. Sacks ◽  
Michel P. Hermans ◽  
Gerd Assmann ◽  
W. Brown ◽  
...  
Keyword(s):  

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
S Zafeiropoulos ◽  
I.T Farmakis ◽  
A Kartas ◽  
A Arvanitaki ◽  
A Pagiantza ◽  
...  

Abstract Background According to the latest ESC Guidelines for chronic coronary syndromes (CCS), patients who suffered an acute coronary syndrome (ACS) pass to a chronic stable phase after one year. In these patients the estimated 10-year risk for recurrent cardiovascular (CV) events varies considerably. We estimated this risk and the expected risk reduction after optimal control. Methods We applied the SMART risk score in 211 patients one year after an ACS to estimate the 10-year risk for recurrent CV events (subsequent non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death). We assessed the distribution of the estimated risk and the potential risk reduction that might be achieved with an optimal guideline-directed management of modifiable risk factors (systolic blood pressure, low-density lipoprotein cholesterol, smoking and body mass index). Results In our cohort, the median SMART score was 16% [interquartile range (IQR), 9.5–26]. If all modifiable risk factors met guideline-recommended targets, median SMART risk score would be 9.4% (IQR, 5.9–17.1), with 52% of the patients at a 10-year risk <10%, while 10% and 11% at 20–30% and >30% risk respectively. The total median reducible risk was 4.7% (IQR, 1.7–8.8). Conclusions The SMART score had a wide distribution among patients with CCS. Noteworthy, one out of five patients will remain at a >20% 10-year risk, even with optimal risk factors management, clearly underlining that residual risk is an unmet clinical issue, which demands individualized patient care. Baseline and total residual risk score Funding Acknowledgement Type of funding source: None


2008 ◽  
Vol 102 (10) ◽  
pp. 1K-34K ◽  
Author(s):  
Jean-Charles Fruchart ◽  
Frank Sacks ◽  
Michel P. Hermans ◽  
Gerd Assmann ◽  
W. Virgil Brown ◽  
...  

2010 ◽  
Vol 26 (8) ◽  
pp. 1793-1797 ◽  
Author(s):  
J.C. Fruchart ◽  
F.M. Sacks ◽  
M.P. Hermans ◽  

Author(s):  
Shigeshi Yamashita ◽  
Kodo Ito

In the aerospace manufacturing, lots of processes cannot be automated and are performed manually by skilled workers. Because there exist some human error mistakes in such manual working processes, root cause investigations of these mistakes are indispensable and measures are implemented in working processes for preventing repetition of the same mistakes. Although skilled workers have strong confidence that they can complete their work with no mistake, there exist some cases that they cannot recognize their mistakes in practice. In such cases, root cause investigations cannot be performed and no measure is implemented. Such situation may become a serious risk in aerospace manufacturing because a tiny mistake can cause the serious mission failure of aviation system. To reduce such situation, the ergonomic risk reduction method is proposed. Skilled workers try to avoid frustration in performing their tasks and make mistakes through careless behavior. The cause of the frustration is discovered by ergonomic risk reduction method. Work risks can be removed by the progress of the working environment. Such risk reduction method contributes manufacturing organization resiliency. In this paper, we propose an ergonomic human error risk reduction method for skilled workers in Japanese domestic liquid rocket engine manufacturing.


2021 ◽  
Vol 17 (1) ◽  
pp. 155-174 ◽  
Author(s):  
William E Boden ◽  
Seth Baum ◽  
Peter P Toth ◽  
Sergio Fazio ◽  
Deepak L Bhatt

Hypertriglyceridemia is associated with increased cardiovascular disease (CVD) risk. The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) demonstrated that the purified, stable ethyl ester of eicosapentaenoic acid, icosapent ethyl (IPE), added to statins reduced CVD events by 25% (p < 0.001), leading to an expanded indication in the USA. IPE is now approved as an adjunct to maximally tolerated statins to reduce CVD event risk in adults with triglyceride (TG) levels ≥150 mg/dl and either established CVD or diabetes mellitus plus ≥2 additional CVD risk factors. The new indication allows co-administration of IPE for elevated TG levels with statin treatment, enabling effective residual risk reduction in a broader at-risk population beyond what can be achieved with intensive low-density lipoprotein cholesterol control alone.


Sign in / Sign up

Export Citation Format

Share Document